ArticleNeuropsychiatric disease and treatment2026
Changes in Anxiety Severity and Acceptability of Venlafaxine in Generalized Anxiety Disorder in the United States: Results From a Real-World Study.
Article in Neuropsychiatric disease and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Anxiety disorders, including the common generalized anxiety disorder (GAD), are among the leading causes of disability globally. Clinical practice guidelines recommend venlafaxine, a serotonin and norepinephrine reuptake inhibitor, as a first-line pharmacological treatment option for GAD. Methods: This retrospective cohort study utilized longitudinal real-world data from the US-based database, Holmusk NeuroBlu Data, to explore anxiety severity changes following 30-90 days of venlafaxine prescription in adults with GAD. The main outcome was change from baseline (mean and median) in the 7-item Generalized Anxiety Disorder Questionnaire (GAD-7) score, as well as clinically meaningful change (a difference of ≥4 points). Results: Of 756 patients with GAD (78.6% female, 78.4% White, mean [standard deviation] age 38.5 [14.4 years]), 71.8% had a diagnosis of comorbid major depressive disorder (MDD) at baseline and 23.0% had another anxiety/phobic disorder. Median (interquartile range [IQR]) GAD-7 scores decreased significantly (P<0.001) from 14.0 (10.0-18.0) at baseline (-30 to +7 days from first venlafaxine prescription) to 9.0 (5.0-14.0) points at follow-up (30-90 days after first venlafaxine prescription), a median (IQR) change of -3.0 (-8.0-0.0), corresponding to a shift from moderate to mild anxiety severity. Stratified by baseline anxiety severity, symptom improvement was more pronounced among patients with greater baseline severity. Overall, 48.1% of patients had a clinically meaningful decrease of ≥4 points in GAD-7 score, while only 7.5% significantly worsened. Altogether, 63.6% of patients continued venlafaxine for ≥90 days after first venlafaxine prescription. Conclusion: In this real-world cohort, improved GAD-7 scores were observed to be associated with venlafaxine prescription.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.